img

Global Immuno-oncology Therapy Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Immuno-oncology Therapy Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Cancer immunotherapy (sometimes called immuno-oncology) is the use of the immune system to treat cancer.
Due to the COVID-19 pandemic, the global Immuno-oncology Therapy market size was US$ 1233 million in 2022 and is forecast to a readjusted size of US$ 1648.7 million by 2034 with a CAGR of 4.5% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Monoclonal Antibodies accounting for % of the Immuno-oncology Therapy global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The global key companies of Immuno-oncology Therapy include Amgen, AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Roche, GlaxoSmithKline, Janssen Biotech, Merck and Novartis, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Immuno-oncology Therapy market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Immuno-oncology Therapy landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Immuno-oncology Therapy market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Immuno-oncology Therapy market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Immuno-oncology Therapy market. Readers of the report can become informed about current and future trends of the global Immuno-oncology Therapy market and how they will impact market growth during the forecast period.



By Company


Amgen
AstraZeneca
Bristol-Myers Squibb
Eli-Lilly
Roche
GlaxoSmithKline
Janssen Biotech
Merck
Novartis
Pfizer
Sanofi
Spectrum Pharmaceuticals
Takeda
BioNTech SE
Allogene Therapeutics
IMAB-I-Mab Biopharma Co., Ltd.
Arcus Biosciences
Gritstone Oncology
Autolus Therapeutics
Rubius Therapeutics
Segment by Type
Monoclonal Antibodies
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines

Segment by Application


Hospitals
Ambulatory Surgical Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Immuno-oncology Therapy in global and regional level.
Chapter 3Detailed analysis of Immuno-oncology Therapy companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immuno-oncology Therapy revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immuno-oncology Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Monoclonal Antibodies
1.2.3 Immune Checkpoint Inhibitors
1.2.4 Immune System Modulators
1.2.5 Cancer Vaccines
1.3 Market by Application
1.3.1 Global Immuno-oncology Therapy Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Center
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Immuno-oncology Therapy Market Size (2018-2034)
2.2 Immuno-oncology Therapy Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Immuno-oncology Therapy Market Size by Region (2018-2024)
2.4 Global Immuno-oncology Therapy Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Immuno-oncology Therapy Countries Ranking by Market Size
3 Immuno-oncology Therapy Competitive by Company
3.1 Global Immuno-oncology Therapy Revenue by Players
3.1.1 Global Immuno-oncology Therapy Revenue by Players (2018-2024)
3.1.2 Global Immuno-oncology Therapy Market Share by Players (2018-2024)
3.2 Global Immuno-oncology Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Immuno-oncology Therapy Revenue
3.4 Global Immuno-oncology Therapy Market Concentration Ratio
3.4.1 Global Immuno-oncology Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immuno-oncology Therapy Revenue in 2022
3.5 Global Key Players of Immuno-oncology Therapy Head office and Area Served
3.6 Global Key Players of Immuno-oncology Therapy, Product and Application
3.7 Global Key Players of Immuno-oncology Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Immuno-oncology Therapy Breakdown Data by Type
4.1 Global Immuno-oncology Therapy Historic Revenue by Type (2018-2024)
4.2 Global Immuno-oncology Therapy Forecasted Revenue by Type (2024-2034)
5 Global Immuno-oncology Therapy Breakdown Data by Application
5.1 Global Immuno-oncology Therapy Historic Market Size by Application (2018-2024)
5.2 Global Immuno-oncology Therapy Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Immuno-oncology Therapy Revenue by Company (2021-2024)
6.2 North America Immuno-oncology Therapy Revenue by Type (2018-2034)
6.3 North America Immuno-oncology Therapy Revenue by Application (2018-2034)
6.4 North America Immuno-oncology Therapy Revenue by Country (2018-2034)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Immuno-oncology Therapy Revenue by Company (2021-2024)
7.2 Europe Immuno-oncology Therapy Revenue by Type (2018-2034)
7.3 Europe Immuno-oncology Therapy Revenue by Application (2018-2034)
7.4 Europe Immuno-oncology Therapy Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Immuno-oncology Therapy Revenue by Company (2021-2024)
8.2 Asia Pacific Immuno-oncology Therapy Revenue by Type (2018-2034)
8.3 Asia Pacific Immuno-oncology Therapy Revenue by Application (2018-2034)
8.4 Asia Pacific Immuno-oncology Therapy Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Immuno-oncology Therapy Revenue by Company (2021-2024)
9.2 Latin America Immuno-oncology Therapy Revenue by Type (2018-2034)
9.3 Latin America Immuno-oncology Therapy Revenue by Application (2018-2034)
9.4 Latin America Immuno-oncology Therapy Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Immuno-oncology Therapy Revenue by Company (2021-2024)
10.2 Middle East and Africa Immuno-oncology Therapy Revenue by Type (2018-2034)
10.3 Middle East and Africa Immuno-oncology Therapy Revenue by Application (2018-2034)
10.4 Middle East and Africa Immuno-oncology Therapy Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Immuno-oncology Therapy Products and Services
11.1.4 Amgen Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.1.5 Amgen Immuno-oncology Therapy SWOT Analysis
11.1.6 Amgen Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Immuno-oncology Therapy Products and Services
11.2.4 AstraZeneca Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.2.5 AstraZeneca Immuno-oncology Therapy SWOT Analysis
11.2.6 AstraZeneca Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Immuno-oncology Therapy Products and Services
11.3.4 Bristol-Myers Squibb Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.3.5 Bristol-Myers Squibb Immuno-oncology Therapy SWOT Analysis
11.3.6 Bristol-Myers Squibb Recent Development
11.4 Eli-Lilly
11.4.1 Eli-Lilly Company Details
11.4.2 Eli-Lilly Business Overview
11.4.3 Eli-Lilly Immuno-oncology Therapy Products and Services
11.4.4 Eli-Lilly Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.4.5 Eli-Lilly Immuno-oncology Therapy SWOT Analysis
11.4.6 Eli-Lilly Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Immuno-oncology Therapy Products and Services
11.5.4 Roche Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.5.5 Roche Immuno-oncology Therapy SWOT Analysis
11.5.6 Roche Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Immuno-oncology Therapy Products and Services
11.6.4 GlaxoSmithKline Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.6.5 GlaxoSmithKline Immuno-oncology Therapy SWOT Analysis
11.6.6 GlaxoSmithKline Recent Development
11.7 Janssen Biotech
11.7.1 Janssen Biotech Company Details
11.7.2 Janssen Biotech Business Overview
11.7.3 Janssen Biotech Immuno-oncology Therapy Products and Services
11.7.4 Janssen Biotech Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.7.5 Janssen Biotech Immuno-oncology Therapy SWOT Analysis
11.7.6 Janssen Biotech Recent Development
11.8 Merck
11.8.1 Merck Company Details
11.8.2 Merck Business Overview
11.8.3 Merck Immuno-oncology Therapy Products and Services
11.8.4 Merck Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.8.5 Merck Immuno-oncology Therapy SWOT Analysis
11.8.6 Merck Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Immuno-oncology Therapy Products and Services
11.9.4 Novartis Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.9.5 Novartis Immuno-oncology Therapy SWOT Analysis
11.9.6 Novartis Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Details
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Immuno-oncology Therapy Products and Services
11.10.4 Pfizer Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.10.5 Pfizer Immuno-oncology Therapy SWOT Analysis
11.10.6 Pfizer Recent Development
11.11 Sanofi
11.11.1 Sanofi Company Details
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Immuno-oncology Therapy Products and Services
11.11.4 Sanofi Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.11.5 Sanofi Recent Development
11.12 Spectrum Pharmaceuticals
11.12.1 Spectrum Pharmaceuticals Company Details
11.12.2 Spectrum Pharmaceuticals Business Overview
11.12.3 Spectrum Pharmaceuticals Immuno-oncology Therapy Products and Services
11.12.4 Spectrum Pharmaceuticals Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.12.5 Spectrum Pharmaceuticals Recent Development
11.13 Takeda
11.13.1 Takeda Company Details
11.13.2 Takeda Business Overview
11.13.3 Takeda Immuno-oncology Therapy Products and Services
11.13.4 Takeda Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.13.5 Takeda Recent Development
11.14 BioNTech SE
11.14.1 BioNTech SE Company Details
11.14.2 BioNTech SE Business Overview
11.14.3 BioNTech SE Immuno-oncology Therapy Products and Services
11.14.4 BioNTech SE Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.14.5 BioNTech SE Recent Development
11.15 Allogene Therapeutics
11.15.1 Allogene Therapeutics Company Details
11.15.2 Allogene Therapeutics Business Overview
11.15.3 Allogene Therapeutics Immuno-oncology Therapy Products and Services
11.15.4 Allogene Therapeutics Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.15.5 Allogene Therapeutics Recent Development
11.16 IMAB-I-Mab Biopharma Co., Ltd.
11.16.1 IMAB-I-Mab Biopharma Co., Ltd. Company Details
11.16.2 IMAB-I-Mab Biopharma Co., Ltd. Business Overview
11.16.3 IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Products and Services
11.16.4 IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.16.5 IMAB-I-Mab Biopharma Co., Ltd. Recent Development
11.17 Arcus Biosciences
11.17.1 Arcus Biosciences Company Details
11.17.2 Arcus Biosciences Business Overview
11.17.3 Arcus Biosciences Immuno-oncology Therapy Products and Services
11.17.4 Arcus Biosciences Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.17.5 Arcus Biosciences Recent Development
11.18 Gritstone Oncology
11.18.1 Gritstone Oncology Company Details
11.18.2 Gritstone Oncology Business Overview
11.18.3 Gritstone Oncology Immuno-oncology Therapy Products and Services
11.18.4 Gritstone Oncology Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.18.5 Gritstone Oncology Recent Development
11.19 Autolus Therapeutics
11.19.1 Autolus Therapeutics Company Details
11.19.2 Autolus Therapeutics Business Overview
11.19.3 Autolus Therapeutics Immuno-oncology Therapy Products and Services
11.19.4 Autolus Therapeutics Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.19.5 Autolus Therapeutics Recent Development
11.20 Rubius Therapeutics
11.20.1 Rubius Therapeutics Company Details
11.20.2 Rubius Therapeutics Business Overview
11.20.3 Rubius Therapeutics Immuno-oncology Therapy Products and Services
11.20.4 Rubius Therapeutics Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024)
11.20.5 Rubius Therapeutics Recent Development
12 Immuno-oncology Therapy Market Dynamics
12.1 Immuno-oncology Therapy Industry Trends
12.2 Immuno-oncology Therapy Market Drivers
12.3 Immuno-oncology Therapy Market Challenges
12.4 Immuno-oncology Therapy Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Immuno-oncology Therapy Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Immune Checkpoint Inhibitors
Table 4. Key Players of Immune System Modulators
Table 5. Key Players of Cancer Vaccines
Table 6. Global Immuno-oncology Therapy Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 7. Global Immuno-oncology Therapy Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 8. Global Immuno-oncology Therapy Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Immuno-oncology Therapy Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 10. Global Immuno-oncology Therapy Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 11. Global Immuno-oncology Therapy Revenue by Players (2018-2024) & (US$ Million)
Table 12. Global Immuno-oncology Therapy Market Share by Players (2018-2024)
Table 13. Global Top Immuno-oncology Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Therapy as of 2022)
Table 14. Ranking of Global Top Immuno-oncology Therapy Companies by Revenue (US$ Million) in 2022
Table 15. Global 5 Largest Players Market Share by Immuno-oncology Therapy Revenue (CR5 and HHI) & (2018-2024)
Table 16. Global Key Players of Immuno-oncology Therapy, Headquarters and Area Served
Table 17. Global Key Players of Immuno-oncology Therapy, Product and Application
Table 18. Global Key Players of Immuno-oncology Therapy, Date of Enter into This Industry
Table 19. Mergers & Acquisitions, Expansion Plans
Table 20. Global Immuno-oncology Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 21. Global Immuno-oncology Therapy Revenue Market Share by Type (2018-2024)
Table 22. Global Immuno-oncology Therapy Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 23. Global Immuno-oncology Therapy Revenue Market Share by Type (2024-2034)
Table 24. Global Immuno-oncology Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 25. Global Immuno-oncology Therapy Revenue Market Share by Application (2018-2024)
Table 26. Global Immuno-oncology Therapy Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 27. Global Immuno-oncology Therapy Revenue Market Share by Application (2024-2034)
Table 28. North America Immuno-oncology Therapy Revenue by Company (2021-2024) & (US$ Million)
Table 29. North America Immuno-oncology Therapy Revenue by Type (2018-2024) & (US$ Million)
Table 30. North America Immuno-oncology Therapy Revenue by Type (2024-2034) & (US$ Million)
Table 31. North America Immuno-oncology Therapy Revenue by Application (2018-2024) & (US$ Million)
Table 32. North America Immuno-oncology Therapy Revenue by Application (2024-2034) & (US$ Million)
Table 33. North America Immuno-oncology Therapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 34. North America Immuno-oncology Therapy Revenue by Country (2018-2024) & (US$ Million)
Table 35. North America Immuno-oncology Therapy Revenue by Country (2024-2034) & (US$ Million)
Table 36. Europe Immuno-oncology Therapy Revenue by Company (2021-2024) & (US$ Million)
Table 37. Europe Immuno-oncology Therapy Revenue by Type (2018-2024) & (US$ Million)
Table 38. Europe Immuno-oncology Therapy Revenue by Type (2024-2034) & (US$ Million)
Table 39. Europe Immuno-oncology Therapy Revenue by Application (2018-2024) & (US$ Million)
Table 40. Europe Immuno-oncology Therapy Revenue by Application (2024-2034) & (US$ Million)
Table 41. Europe Immuno-oncology Therapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 42. Europe Immuno-oncology Therapy Revenue by Country (2018-2024) & (US$ Million)
Table 43. Europe Immuno-oncology Therapy Revenue by Country (2024-2034) & (US$ Million)
Table 44. Asia Pacific Immuno-oncology Therapy Revenue by Company (2021-2024) & (US$ Million)
Table 45. Asia Pacific Immuno-oncology Therapy Revenue by Type (2018-2024) & (US$ Million)
Table 46. Asia Pacific Immuno-oncology Therapy Revenue by Type (2024-2034) & (US$ Million)
Table 47. Asia Pacific Immuno-oncology Therapy Revenue by Application (2018-2024) & (US$ Million)
Table 48. Asia Pacific Immuno-oncology Therapy Revenue by Application (2024-2034) & (US$ Million)
Table 49. Asia-Pacific Immuno-oncology Therapy Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 50. Asia Pacific Immuno-oncology Therapy Revenue by Region (2018-2024) & (US$ Million)
Table 51. Asia Pacific Immuno-oncology Therapy Revenue by Region (2024-2034) & (US$ Million)
Table 52. Latin America Immuno-oncology Therapy Revenue by Company (2021-2024) & (US$ Million)
Table 53. Latin America Immuno-oncology Therapy Revenue by Type (2018-2024) & (US$ Million)
Table 54. Latin America Immuno-oncology Therapy Revenue by Type (2024-2034) & (US$ Million)
Table 55. Latin America Immuno-oncology Therapy Revenue by Application (2018-2024) & (US$ Million)
Table 56. Latin America Immuno-oncology Therapy Revenue by Application (2024-2034) & (US$ Million)
Table 57. Latin America Immuno-oncology Therapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 58. Latin America Immuno-oncology Therapy Revenue by Country (2018-2024) & (US$ Million)
Table 59. Latin America Immuno-oncology Therapy Revenue by Country (2024-2034) & (US$ Million)
Table 60. Middle East and Africa Immuno-oncology Therapy Revenue by Company (2021-2024) & (US$ Million)
Table 61. Middle East and Africa Immuno-oncology Therapy Revenue by Type (2018-2024) & (US$ Million)
Table 62. Middle East and Africa Immuno-oncology Therapy Revenue by Type (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Immuno-oncology Therapy Revenue by Application (2018-2024) & (US$ Million)
Table 64. Middle East and Africa Immuno-oncology Therapy Revenue by Application (2024-2034) & (US$ Million)
Table 65. Middle East and Africa Immuno-oncology Therapy Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 66. Middle East and Africa Immuno-oncology Therapy Revenue by Country (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Immuno-oncology Therapy Revenue by Country (2024-2034) & (US$ Million)
Table 68. Amgen Company Details
Table 69. Amgen Business Overview
Table 70. Amgen Immuno-oncology Therapy Product and Services
Table 71. Amgen Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 72. Amgen Immuno-oncology Therapy SWOT Analysis
Table 73. Amgen Recent Development
Table 74. AstraZeneca Company Details
Table 75. AstraZeneca Business Overview
Table 76. AstraZeneca Immuno-oncology Therapy Product and Services
Table 77. AstraZeneca Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 78. AstraZeneca Immuno-oncology Therapy SWOT Analysis
Table 79. AstraZeneca Recent Development
Table 80. Bristol-Myers Squibb Company Details
Table 81. Bristol-Myers Squibb Business Overview
Table 82. Bristol-Myers Squibb Immuno-oncology Therapy Product and Services
Table 83. Bristol-Myers Squibb Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 84. Bristol-Myers Squibb Immuno-oncology Therapy SWOT Analysis
Table 85. Bristol-Myers Squibb Recent Development
Table 86. Eli-Lilly Company Details
Table 87. Eli-Lilly Business Overview
Table 88. Eli-Lilly Immuno-oncology Therapy Product and Services
Table 89. Eli-Lilly Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 90. Eli-Lilly Immuno-oncology Therapy SWOT Analysis
Table 91. Eli-Lilly Recent Development
Table 92. Roche Company Details
Table 93. Roche Business Overview
Table 94. Roche Immuno-oncology Therapy Product and Services
Table 95. Roche Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 96. Roche Immuno-oncology Therapy SWOT Analysis
Table 97. Roche Recent Development
Table 98. GlaxoSmithKline Company Details
Table 99. GlaxoSmithKline Business Overview
Table 100. GlaxoSmithKline Immuno-oncology Therapy Product and Services
Table 101. GlaxoSmithKline Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 102. GlaxoSmithKline Immuno-oncology Therapy SWOT Analysis
Table 103. GlaxoSmithKline Recent Development
Table 104. Janssen Biotech Company Details
Table 105. Janssen Biotech Business Overview
Table 106. Janssen Biotech Immuno-oncology Therapy Product and Services
Table 107. Janssen Biotech Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 108. Janssen Biotech Immuno-oncology Therapy SWOT Analysis
Table 109. Janssen Biotech Recent Development
Table 110. Merck Company Details
Table 111. Merck Business Overview
Table 112. Merck Immuno-oncology Therapy Product and Services
Table 113. Merck Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 114. Merck Immuno-oncology Therapy SWOT Analysis
Table 115. Merck Recent Development
Table 116. Novartis Company Details
Table 117. Novartis Business Overview
Table 118. Novartis Immuno-oncology Therapy Product and Services
Table 119. Novartis Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 120. Novartis Immuno-oncology Therapy SWOT Analysis
Table 121. Novartis Recent Development
Table 122. Pfizer Company Details
Table 123. Pfizer Business Overview
Table 124. Pfizer Immuno-oncology Therapy Product and Services
Table 125. Pfizer Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 126. Pfizer Immuno-oncology Therapy SWOT Analysis
Table 127. Pfizer Recent Development
Table 128. Sanofi Company Details
Table 129. Sanofi Business Overview
Table 130. Sanofi Immuno-oncology Therapy Product and Services
Table 131. Sanofi Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 132. Sanofi Recent Development
Table 133. Spectrum Pharmaceuticals Company Details
Table 134. Spectrum Pharmaceuticals Business Overview
Table 135. Spectrum Pharmaceuticals Immuno-oncology Therapy Product and Services
Table 136. Spectrum Pharmaceuticals Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 137. Spectrum Pharmaceuticals Recent Development
Table 138. Takeda Company Details
Table 139. Takeda Business Overview
Table 140. Takeda Immuno-oncology Therapy Product and Services
Table 141. Takeda Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 142. Takeda Recent Development
Table 143. BioNTech SE Company Details
Table 144. BioNTech SE Business Overview
Table 145. BioNTech SE Immuno-oncology Therapy Product and Services
Table 146. BioNTech SE Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 147. BioNTech SE Recent Development
Table 148. Allogene Therapeutics Company Details
Table 149. Allogene Therapeutics Business Overview
Table 150. Allogene Therapeutics Immuno-oncology Therapy Product and Services
Table 151. Allogene Therapeutics Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 152. Allogene Therapeutics Recent Development
Table 153. IMAB-I-Mab Biopharma Co., Ltd. Company Details
Table 154. IMAB-I-Mab Biopharma Co., Ltd. Business Overview
Table 155. IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Product and Services
Table 156. IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 157. IMAB-I-Mab Biopharma Co., Ltd. Recent Development
Table 158. Arcus Biosciences Company Details
Table 159. Arcus Biosciences Business Overview
Table 160. Arcus Biosciences Immuno-oncology Therapy Product and Services
Table 161. Arcus Biosciences Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 162. Arcus Biosciences Recent Development
Table 163. Gritstone Oncology Company Details
Table 164. Gritstone Oncology Business Overview
Table 165. Gritstone Oncology Immuno-oncology Therapy Product and Services
Table 166. Gritstone Oncology Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 167. Gritstone Oncology Recent Development
Table 168. Autolus Therapeutics Company Details
Table 169. Autolus Therapeutics Business Overview
Table 170. Autolus Therapeutics Immuno-oncology Therapy Product and Services
Table 171. Autolus Therapeutics Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 172. Autolus Therapeutics Recent Development
Table 173. Rubius Therapeutics Company Details
Table 174. Rubius Therapeutics Business Overview
Table 175. Rubius Therapeutics Immuno-oncology Therapy Product and Services
Table 176. Rubius Therapeutics Immuno-oncology Therapy Revenue in Immuno-oncology Therapy Business (2018-2024) & (US$ Million)
Table 177. Rubius Therapeutics Recent Development
Table 178. Immuno-oncology Therapy Market Trends
Table 179. Immuno-oncology Therapy Market Drivers
Table 180. Immuno-oncology Therapy Market Challenges
Table 181. Immuno-oncology Therapy Market Restraints
Table 182. Research Programs/Design for This Report
Table 183. Key Data Information from Secondary Sources
Table 184. Key Data Information from Primary Sources
List of Figures
Figure 1. Immuno-oncology Therapy Product Picture
Figure 2. Global Immuno-oncology Therapy Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Immuno-oncology Therapy Market Share by Type: 2022 VS 2034
Figure 4. Monoclonal Antibodies Features
Figure 5. Immune Checkpoint Inhibitors Features
Figure 6. Immune System Modulators Features
Figure 7. Cancer Vaccines Features
Figure 8. Global Immuno-oncology Therapy Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 9. Global Immuno-oncology Therapy Market Share by Application: 2022 VS 2034
Figure 10. Hospitals
Figure 11. Ambulatory Surgical Center
Figure 12. Others
Figure 13. Immuno-oncology Therapy Report Years Considered
Figure 14. Global Immuno-oncology Therapy Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Immuno-oncology Therapy Market Size 2018-2034 (US$ Million)
Figure 16. Global Immuno-oncology Therapy Market Size Market Share by Region: 2022 VS 2034
Figure 17. Global Immuno-oncology Therapy Revenue Market Share by Region in 2018 VS 2022
Figure 18. Global Immuno-oncology Therapy Revenue Market Share Forecast by Region (2024-2034)
Figure 19. Global Top 10 Immuno-oncology Therapy Countries Ranking by Market Size (US$ Million) in 2022
Figure 20. Global Immuno-oncology Therapy Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 21. Global Immuno-oncology Therapy Market Share by Players in 2022
Figure 22. Global Top Immuno-oncology Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Therapy as of 2022)
Figure 23. The Top 10 and 5 Players Market Share by Immuno-oncology Therapy Revenue in 2022
Figure 24. North America Immuno-oncology Therapy Revenue Market Share by Company in 2022
Figure 25. North America Immuno-oncology Therapy Revenue Market Share by Type (2018-2034)
Figure 26. North America Immuno-oncology Therapy Revenue Market Share by Application (2018-2034)
Figure 27. North America Immuno-oncology Therapy Revenue Share by Country (2018-2034)
Figure 28. United States Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 29. Canada Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 30. Europe Immuno-oncology Therapy Revenue Market Share by Company in 2022
Figure 31. Europe Immuno-oncology Therapy Revenue Market Share by Type (2018-2034)
Figure 32. Europe Immuno-oncology Therapy Revenue Market Share by Application (2018-2034)
Figure 33. Europe Immuno-oncology Therapy Revenue Share by Country (2018-2034)
Figure 34. Germany Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 35. France Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 36. U.K. Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 37. Italy Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 38. Russia Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 39. Asia Pacific Immuno-oncology Therapy Revenue Market Share by Company in 2022
Figure 40. Asia Pacific Immuno-oncology Therapy Revenue Market Share by Type (2018-2034)
Figure 41. Asia Pacific Immuno-oncology Therapy Revenue Market Share by Application (2018-2034)
Figure 42. Asia Pacific Immuno-oncology Therapy Revenue Share by Region (2018-2034)
Figure 43. China Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 44. Japan Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 45. South Korea Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 46. India Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 47. Australia Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 48. China Taiwan Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 49. Indonesia Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 50. Thailand Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 51. Malaysia Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 52. Latin America Immuno-oncology Therapy Revenue Market Share by Company in 2022
Figure 53. Latin America Immuno-oncology Therapy Revenue Market Share by Type (2018-2034)
Figure 54. Latin America Immuno-oncology Therapy Revenue Market Share by Application (2018-2034)
Figure 55. Latin America Immuno-oncology Therapy Revenue Share by Country (2018-2034)
Figure 56. Mexico Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 57. Brazil Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 58. Argentina Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 59. Middle East and Africa Immuno-oncology Therapy Revenue Market Share by Company in 2022
Figure 60. Middle East and Africa Immuno-oncology Therapy Revenue Market Share by Type (2018-2034)
Figure 61. Middle East and Africa Immuno-oncology Therapy Revenue Market Share by Application (2018-2034)
Figure 62. Middle East and Africa Immuno-oncology Therapy Revenue Share by Country (2018-2034)
Figure 63. Turkey Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 64. Saudi Arabia Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 65. UAE Immuno-oncology Therapy Revenue (2018-2034) & (US$ Million)
Figure 66. Amgen Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 67. AstraZeneca Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 68. Bristol-Myers Squibb Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 69. Eli-Lilly Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 70. Roche Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 71. GlaxoSmithKline Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 72. Janssen Biotech Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 73. Merck Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 74. Novartis Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 75. Pfizer Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 76. Sanofi Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 77. Spectrum Pharmaceuticals Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 78. Takeda Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 79. BioNTech SE Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 80. Allogene Therapeutics Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 81. IMAB-I-Mab Biopharma Co., Ltd. Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 82. Arcus Biosciences Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 83. Gritstone Oncology Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 84. Autolus Therapeutics Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 85. Rubius Therapeutics Revenue Growth Rate in Immuno-oncology Therapy Business (2018-2024)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries